Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 556 to 570 of 1136 results for pain

  1. Insertion of a double balloon catheter for induction of labour in pregnant women without previous caesarean section (IPG528)

    Evidence-based recommendations on insertion of a double balloon catheter for induction of labour in pregnant women without previous caesarean section. The catheter aims to help induction by causing dilation of the cervix when the cervix is unfavourable for induction. The double balloon squeezes the cervix and stimulates local prostaglandin release, which leads to cervical ripening.

    Interventional procedures guidance
    Published
    23 July 2015
    View recommendations

    Sections for IPG528

  2. Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis (IPG523)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for deep vein thrombosis. This involves using ultrasound waves and a drug to break up the clot.

    Interventional procedures guidance
    Published
    26 June 2015
    View recommendations

    Sections for IPG523

  3. Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)

    Evidence-based recommendations on darvadstrocel (Alofisel) for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn’s disease.

    Technology appraisal guidance
    Published
    9 January 2019
    View recommendations

    Sections for TA556

  4. Endoscopic mucosal resection and endoscopic submucosal dissection of non-ampullary duodenal lesions (IPG359)

    Evidence-based recommendations on endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) of non-ampullary duodenal lesions. This involves using a long camera inserted through the mouth to view the area and removing the abnormal parts of the lining with special instruments.

    Interventional procedures guidance
    Published
    27 October 2010
    View recommendations

    Sections for IPG359

  5. Randomised controlled trials comparing Prontosan with saline or water in the NHS are needed. The committee concluded that further research is needed to address the uncertainties about the clinical effectiveness of Prontosan compared with saline or water. It recommended that randomised controlled trials should be done in the NHS. These should compare Prontosan with saline or water in different types of chronic wounds. The randomised controlled trial needs to be well designed to detect clinically meaningful results in subgroups (for example, pressure ulcers or venous leg ulcers). The committee agreed that a key outcome should be time to complete wound healing. The number of dressing changes should also be recorded for each wound included in the study. Other important outcomes should include pain and wound odour, measured using patient reported outcome measures (PROMs).

    each wound included in the study. Other important outcomes should include pain and wound odour, measured using patient reported outcome...

    Research recommendation
    Published
    8 April 2022

  6. Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)

    NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .

    Medtech innovation briefing
    Published
    18 January 2017

  7. Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism (IPG778)

    Evidence-based recommendations on percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism. This involves removing the clot through a catheter inserted into a vein.

    Interventional procedures guidance
    Published
    29 November 2023
    View recommendations

    Sections for IPG778

  8. Evidence on the efficacy and safety of neurostimulation of lumbar muscles for refractory non-specific chronic low back pain is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    neurostimulation of lumbar muscles for refractory non-specific chronic low back pain is limited in quantity and quality. Therefore, this...

    Research recommendation
    Published
    30 September 2022

  9. Gastroparesis in adults: oral erythromycin (ESUOM13)

    Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    18 June 2013

  10. Erectile dysfunction: Alprostadil cream (ESNM50)

    Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 December 2014

  11. The STAK tool for preventing and treating knee stiffness (MIB252)

    NICE has developed a medtech innovation briefing (MIB) on the STAK tool for preventing and treating knee stiffness .

    Medtech innovation briefing
    Published
    9 February 2021

  12. Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)

    Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.

    Technology appraisal guidance
    Published
    4 October 2017
    View recommendations

    Sections for TA477

  13. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)

    Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.

    Technology appraisal guidance
    Published
    27 April 2016
    View recommendations

    Sections for TA389

  14. Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)

    Evidence-based recommendations on diroximel fumarate (Vumerity) for active relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    8 June 2022
    View recommendations

    Sections for TA794

  15. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.

    Technology appraisal guidance
    Published
    26 July 2017
    View recommendations

    Sections for TA461